Resources for Patients and their Families

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have mesothelioma of the lung.

Tracking Information
First Received DateFebruary 14, 2002
Last Changed DateMay 14, 2012
Start DateJune 2000
Actual Primary Completion DateMay 2003
Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Malignant Mesothelioma
  • Drug: cisplatin
  • Drug: gemcitabine hydrochloride
  • Procedure: conventional surgery
Detailed Description


- Determine the proportion of patients with potentially resectable mesothelioma of the pleura remaining operable after treatment with neoadjuvant cisplatin and gemcitabine.

- Determine the response rate and overall survival of patients treated with this regimen.

- Determine the tolerability of this regimen in these patients.

- Determine the number of postoperative hospitalization days and occurrence and duration of surgical complications in patients treated with this regimen.

- Determine the quality of life of patients treated with this regimen.

- Compare the proportion of patients who report psychological distress at 3 months after surgery vs at study registration.

OUTLINE: Patients receive cisplatin IV on day 1 and gemcitabine IV on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses. Within 6 weeks after completion of chemotherapy, patients undergo restaging by CT scan followed by surgical resection.

Quality of life is assessed at baseline, day 1 of course 3, within 4 weeks after surgery, and then at 3 and 6 months.

Patients are followed every 3 months for 1 year and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 61 patients will be accrued for this study.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment61
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria


- Histologically and clinically confirmed pleural mesothelioma

- Stages T1-3, N0-2, M0 by CT scan of the chest

- Mediastinoscopy required for staging of mediastinal lymph nodes

- Considered completely resectable



- Over 18

Performance status:

- WHO 0-2

Life expectancy:

- Not specified


- Not specified


- No severe liver disease


- Creatinine no greater than 1.7 mg/dL


- Adequate cardiac function

- No cardiac disease that would preclude forced hydration or surgery


- Predicted postoperative FEV_1 greater than 1 by spirometry


- No contraindication to surgery

- No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer

- No uncontrolled infection

- No uncontrolled diabetes

- No neurologic or psychiatric disorders that would preclude study compliance

- No other serious illnesses that would preclude study participation

- No other circumstances that would preclude study participation


Biologic therapy

- Not specified


- Not specified

Endocrine therapy

- Not specified


- Not specified


- No prior pleurectomy or lung resection except for diagnostic purposes

Administrative Information
Responsible PartySponsor
SponsorSwiss Group for Clinical Cancer Research
Verification DateMay 2012
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Fall 2018 Mesothelioma Cancer Alliance Scholarship Winner Darwin Arias

Prognosis of Mesothelioma Without Treatment

Asbestos Is No Laughing Matter

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: